Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan add-on to C5 inhibitors in pediatric PNH with extravascular hemolysis
NCT06449001Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change From Baseline in Hemoglobin Concentration at Week 12. Started Aug 2025; status: recruiting.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06449001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449001.